Taisho Pharmaceutical Holdings Co., Ltd.
4581
Classificação em ações
#3723
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Preço da ação
$54.31
Última sincronização: 2024-04-08
Valor de mercado
$4.45B
Variação (1 dia)
-4.14%
Variação (1 ano)
0.00%
País
JP
Negociar Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Categoria
Healthcare
Margem Operacional de Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Taisho Pharmaceutical Holdings Co., Ltd., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Taisho Pharmaceutical Holdings Co., Ltd. de 2006 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2023 | 7.64% | 90.52% |
| 2022 | 4.01% | -43.36% |
| 2021 | 7.08% | -4.71% |
| 2020 | 7.43% | -37.77% |
| 2019 | 11.94% | -9.55% |
| 2018 | 13.20% | 15.49% |
| 2017 | 11.43% | 14.76% |
| 2016 | 9.96% | -9.54% |
| 2015 | 11.01% | -21.80% |
| 2014 | 14.08% | 13.64% |
| 2013 | 12.39% | -12.50% |
| 2012 | 14.16% | -13.71% |
| 2011 | 16.41% | 22.28% |
| 2010 | 13.42% | -9.32% |
| 2009 | 14.80% | -19.30% |
| 2008 | 18.34% | 35.75% |
| 2007 | 13.51% | -37.31% |
| 2006 | 21.55% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | - |
IN
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.